Brii Biosciences Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Zhi Hong
- Full Time Employees
- 75
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Building 7 Haidian BE China 100192
- IPO Date
- Jul 13, 2021
- Website
- briibio.com
- Similar Companies
- Business
- Brii Biosciences Limited Brii Biosciences Limited (2137.HK) is a biotechnology company that develops innovative therapies targeting infectious diseases, including chronic hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensively drug-resistant (XDR) gram-negative bacterial infections, and central nervous system disorders; its lead HBV functional cure portfolio comprises the recombinant protein-based immunotherapeutic BRII-179, the HBV-targeting siRNA elebsiran (previously BRII-835), and the neutralizing monoclonal antibody tobevibart (previously BRII-877), alongside HIV long-acting candidates BRII-732 and BRII-753, the synthetic lipopeptide BRII-693 for MDR/XDR gram-negative infections, and epetraborole (previously BRII-658) for nontuberculous mycobacterial (NTM) lung disease. Founded in 2017 and headquartered in Beijing, China, with additional operations in the United States including Durham, North Carolina, and San Mateo, California, the company primarily operates in Greater China while holding global rights to select assets and pursues clinical development through in-house research, strategic partnerships, and collaborations with organizations such as Vir Biotechnology and Joincare Pharmaceutical Group Industry Co., Ltd. Brii Biosciences targets patients with high unmet needs in the world's largest HBV market in China and advances multiple Phase 2 trials including ENSURE (elebsiran plus pegylated interferon alpha), ENRICH (BRII-179 sequential with elebsiran and pegylated interferon alpha), and ENHANCE (triple combination of BRII-179, elebsiran, and pegylated interferon alpha), all of which received Breakthrough Therapy Designation from China's NMPA. In recent developments, the company completed enrollment in the ENHANCE study in January 2025 and anticipates key data readouts from ongoing HBV trials through 2025-2026; secured full intellectual property rights to BRII-179 via an asset purchase from VBI Vaccines in December 2024 for US$18 million, eliminating future royalties; entered a strategic licensing agreement with Joincare Group in July 2025 for soralimixin (BRII-693) development and commercialization in Greater China; received IND approval from China's CDE in October 2024 for a Phase 1 pharmacokinetic bridging study of BRII-693; and initiated a HK$60 million share buyback program in December 2024.
Company News
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
Brii Biosciences Limited (BRIBF) Q4 2025 Earnings Call Transcript
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results